FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
0
0
0 Pogledi·
09/21/23
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
Prikaži više
0 Komentari
sort Poredaj po